Literature DB >> 31798381

Luminal Metastatic Breast Cancer.

Jens Huober1, Rupert Bartsch2, Frederik Marmé3, Olivia Pagani4, Christoph Thomssen5.   

Abstract

Entities:  

Year:  2019        PMID： 31798381      PMCID： PMC6886107          DOI： 10.1159/000499440

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  3 in total

1.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Authors:  Jennifer K Litton; Hope S Rugo; Johannes Ettl; Sara A Hurvitz; Anthony Gonçalves; Kyung-Hun Lee; Louis Fehrenbacher; Rinat Yerushalmi; Lida A Mina; Miguel Martin; Henri Roché; Young-Hyuck Im; Ruben G W Quek; Denka Markova; Iulia C Tudor; Alison L Hannah; Wolfgang Eiermann; Joanne L Blum
Journal:  N Engl J Med       Date:  2018-08-15       Impact factor: 91.245

2.  Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Angelo Di Leo; Stephen Johnston; Keun Seok Lee; Eva Ciruelos; Per E Lønning; Wolfgang Janni; Ruth O'Regan; Marie-Ange Mouret-Reynier; Dimitar Kalev; Daniel Egle; Tibor Csőszi; Roberto Bordonaro; Thomas Decker; Vivianne C G Tjan-Heijnen; Sibel Blau; Alessio Schirone; Denis Weber; Mona El-Hashimy; Bharani Dharan; Dalila Sellami; Thomas Bachelot
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

3.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.